Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386966516> ?p ?o ?g. }
- W4386966516 abstract "Introduction: The availability of highly effective triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapy with elexacaftor-tezacaftor-ivacaftor (ETI) has improved pulmonary outcomes and quality of life of people with cystic fibrosis (pwCF). The aim of this study was to assess computed tomography (CT) changes under ETI visually with the Brody score and quantitatively with dedicated software, and to correlate CT measures with parameters of clinical response. Methods: Twenty two adult pwCF with two consecutive CT scans before and after ETI treatment initiation were retrospectively included. CT was assessed visually employing the Brody score and quantitatively by YACTA, a well-evaluated scientific software computing airway dimensions and lung parenchyma with wall percentage (WP), wall thickness (WT), lumen area (LA), bronchiectasis index (BI), lung volume and mean lung density (MLD) as parameters. Changes in CT metrics were evaluated and the visual and quantitative parameters were correlated with each other and with clinical changes in sweat chloride concentration, spirometry [percent predicted of forced expiratory volume in one second (ppFEV1)] and body mass index (BMI). Results: The mean (SD) Brody score improved with ETI [55 (12) vs. 38 (15); p < 0.001], incl. sub-scores for mucus plugging, peribronchial thickening, and parenchymal changes (all p < 0.001), but not for bronchiectasis (p = 0.281). Quantitatve WP (p < 0.001) and WT (p = 0.004) were reduced, conversely LA increased (p = 0.003), and BI improved (p = 0.012). Lung volume increased (p < 0.001), and MLD decreased (p < 0.001) through a reduction of ground glass opacity areas (p < 0.001). Changes of the Brody score correlated with those of quantitative parameters, exemplarily WT with the sub-score for mucus plugging (r = 0.730, p < 0.001) and peribronchial thickening (r = 0.552, p = 0.008). Changes of CT parameters correlated with those of clinical response parameters, in particular ppFEV1 with the Brody score (r = -0.606, p = 0.003) and with WT (r = -0.538, p = 0.010). Discussion: Morphological treatment response to ETI can be assessed using the Brody score as well as quantitative CT parameters. Changes in CT correlated with clinical improvements. The quantitative analysis with YACTA proved to be an objective, reproducible and simple method for monitoring lung disease, particularly with regard to future interventional clinical trials." @default.
- W4386966516 created "2023-09-23" @default.
- W4386966516 creator A5015271937 @default.
- W4386966516 creator A5017464354 @default.
- W4386966516 creator A5059857876 @default.
- W4386966516 creator A5075380514 @default.
- W4386966516 creator A5079062707 @default.
- W4386966516 creator A5079894868 @default.
- W4386966516 creator A5086339272 @default.
- W4386966516 creator A5088938129 @default.
- W4386966516 creator A5092923771 @default.
- W4386966516 date "2023-09-21" @default.
- W4386966516 modified "2023-10-11" @default.
- W4386966516 title "Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study" @default.
- W4386966516 cites W1971317693 @default.
- W4386966516 cites W1973440296 @default.
- W4386966516 cites W1976926329 @default.
- W4386966516 cites W1994869590 @default.
- W4386966516 cites W2016388542 @default.
- W4386966516 cites W2019585154 @default.
- W4386966516 cites W2037789035 @default.
- W4386966516 cites W2054404145 @default.
- W4386966516 cites W2077003803 @default.
- W4386966516 cites W2078678726 @default.
- W4386966516 cites W2087334060 @default.
- W4386966516 cites W2089674071 @default.
- W4386966516 cites W2102634410 @default.
- W4386966516 cites W2106925733 @default.
- W4386966516 cites W2111004044 @default.
- W4386966516 cites W2131118203 @default.
- W4386966516 cites W2144102711 @default.
- W4386966516 cites W2149205672 @default.
- W4386966516 cites W2335878270 @default.
- W4386966516 cites W2400611618 @default.
- W4386966516 cites W2753747319 @default.
- W4386966516 cites W2792598062 @default.
- W4386966516 cites W2887185316 @default.
- W4386966516 cites W2979759357 @default.
- W4386966516 cites W2982296199 @default.
- W4386966516 cites W2985405196 @default.
- W4386966516 cites W3001360060 @default.
- W4386966516 cites W3089095538 @default.
- W4386966516 cites W3112597476 @default.
- W4386966516 cites W3151103866 @default.
- W4386966516 cites W3159147450 @default.
- W4386966516 cites W3178680242 @default.
- W4386966516 cites W3200506391 @default.
- W4386966516 cites W3212982780 @default.
- W4386966516 cites W4200355041 @default.
- W4386966516 cites W4205612199 @default.
- W4386966516 cites W4214721068 @default.
- W4386966516 cites W4225996536 @default.
- W4386966516 cites W4280526703 @default.
- W4386966516 cites W4281617162 @default.
- W4386966516 cites W4288696142 @default.
- W4386966516 cites W4318191461 @default.
- W4386966516 cites W4318615933 @default.
- W4386966516 cites W4319022986 @default.
- W4386966516 cites W4361268617 @default.
- W4386966516 cites W4378473123 @default.
- W4386966516 cites W4383104432 @default.
- W4386966516 doi "https://doi.org/10.3389/fphar.2023.1245885" @default.
- W4386966516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37808186" @default.
- W4386966516 hasPublicationYear "2023" @default.
- W4386966516 type Work @default.
- W4386966516 citedByCount "0" @default.
- W4386966516 crossrefType "journal-article" @default.
- W4386966516 hasAuthorship W4386966516A5015271937 @default.
- W4386966516 hasAuthorship W4386966516A5017464354 @default.
- W4386966516 hasAuthorship W4386966516A5059857876 @default.
- W4386966516 hasAuthorship W4386966516A5075380514 @default.
- W4386966516 hasAuthorship W4386966516A5079062707 @default.
- W4386966516 hasAuthorship W4386966516A5079894868 @default.
- W4386966516 hasAuthorship W4386966516A5086339272 @default.
- W4386966516 hasAuthorship W4386966516A5088938129 @default.
- W4386966516 hasAuthorship W4386966516A5092923771 @default.
- W4386966516 hasBestOaLocation W43869665161 @default.
- W4386966516 hasConcept C105922876 @default.
- W4386966516 hasConcept C126322002 @default.
- W4386966516 hasConcept C126838900 @default.
- W4386966516 hasConcept C141071460 @default.
- W4386966516 hasConcept C27101514 @default.
- W4386966516 hasConcept C2776042228 @default.
- W4386966516 hasConcept C2776502428 @default.
- W4386966516 hasConcept C2776938444 @default.
- W4386966516 hasConcept C2777714996 @default.
- W4386966516 hasConcept C2778428886 @default.
- W4386966516 hasConcept C2779379686 @default.
- W4386966516 hasConcept C2780221984 @default.
- W4386966516 hasConcept C2780333948 @default.
- W4386966516 hasConcept C2989005 @default.
- W4386966516 hasConcept C544519230 @default.
- W4386966516 hasConcept C71924100 @default.
- W4386966516 hasConcept C90924648 @default.
- W4386966516 hasConceptScore W4386966516C105922876 @default.
- W4386966516 hasConceptScore W4386966516C126322002 @default.
- W4386966516 hasConceptScore W4386966516C126838900 @default.
- W4386966516 hasConceptScore W4386966516C141071460 @default.
- W4386966516 hasConceptScore W4386966516C27101514 @default.
- W4386966516 hasConceptScore W4386966516C2776042228 @default.